lapatinib has been researched along with Acute Liver Injury, Drug-Induced in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (92.31) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Norman, BH | 1 |
| Ahmed, S; Andersson, M; Armour, A; Aziz, Z; Briley, LP; Byrne, J; Crescenzo, R; Demetriou, G; Fraser, DJ; Gralow, J; Harris, L; Jackson, N; Jiang, Z; Mehta, A; Parham, LR; Perez, E; Piccart, M; Spraggs, CF; Toi, M; Warren, L; Williams, LS; Zujewski, JA | 1 |
| Gwak, HS; Han, JM; Moon, JY; Seo, I | 1 |
| Kongkaew, C; Lohitnavy, M; Scholfield, CN; Subongkot, S; Tangamornsuksan, W | 1 |
| Hunt, CM; Spraggs, CF; Xu, CF | 1 |
| Kaniwa, N; Saito, Y | 1 |
| Agbor-Tarh, D; Aktas, B; Azim, HA; Baselga, J; Bradbury, I; de Azambuja, E; Di Cosimo, S; Dinh, P; Dreosti, L; Eidtmann, H; Greger, JG; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Piccart, M; Smith, I; Vuylsteke, P | 1 |
| Cardon, LR; Cox, CJ; Curran, J; Ejlertsen, B; Finkelstein, DM; Goss, PE; McDonnell, SK; Parham, LR; Rappold, E; Schaid, DJ; Spraggs, CF | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Briley, LP; Cox, CJ; Dilthey, A; Iqbal, Z; King, KS; Li, L; McVean, G; Nelson, MR; Newcombe, PJ; Parham, LR; Shen, J; Slater, AJ; Spraggs, CF | 1 |
| Hagihara, K; Hirasawa, M; Izumi, T; Okudaira, N | 1 |
| de la Cruz Merino, L; Marcos Rodríguez, JA; Romero Carreño, E; Santana Martínez, S | 1 |
| Faulkner, L; Meng, X; Naisbitt, DJ; Park, BK; Spraggs, CF | 1 |
| Aklillu, E; Makonnen, E; Petros, Z | 1 |
| Chan, EC; Hanson, KL; Nelson, SD; New, LS; Takakusa, H; Wahlin, MD; Zhao, C | 1 |
| Kalofonos, H; Koutras, A; Labropoulou-Karatza, C; Makatsoris, T; Onyenadum, A; Peroukides, S; Tsamandas, A | 1 |
| Borts, DJ; Bowers, GD; Castellino, S; Koch, K; MacLauchlin, C; O'Mara, M | 1 |
| Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Kerem, M; Pasali, H; Pasaoglu, H; Uner, A; Yılmaz, G | 1 |
| Dollery, CT; Hunt, CM; Parham, LR; Spraggs, CF | 1 |
6 review(s) available for lapatinib and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; Female; HLA-DRB1 Chains; Humans; Lapatinib | 2020 |
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
Topics: Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Gilbert Disease; Glucuronosyltransferase; Humans; Indazoles; Lapatinib; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Topics: Alleles; Allopurinol; Amoxicillin-Potassium Clavulanate Combination; Azetidines; Benzylamines; Carbamazepine; Chemical and Drug Induced Liver Injury; Diclofenac; Dideoxynucleosides; Drug Hypersensitivity; Floxacillin; Genetic Markers; HLA Antigens; HLA-A Antigens; HLA-B Antigens; HLA-DQ alpha-Chains; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Skin; Stevens-Johnson Syndrome; Ticlopidine | 2013 |
Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatigue; Humans; Lapatinib; Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2014 |
5 trial(s) available for lapatinib and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Liver; Neoplasm Staging; Risk Factors; Taxoids; Trastuzumab | 2018 |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Female; Humans; Incidence; Lapatinib; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2013 |
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Topics: Alanine Transaminase; Alleles; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Genome-Wide Association Study; HLA-DRB1 Chains; Humans; Hyperbilirubinemia; INDEL Mutation; Lapatinib; Polymorphism, Single Nucleotide; Quinazolines; Risk | 2016 |
Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.
Topics: Alanine Transaminase; Chemical and Drug Induced Liver Injury; Genotype; Gilbert Disease; Glucuronosyltransferase; HLA-DQ alpha-Chains; HLA-DRB1 Chains; Humans; Incidence; Lapatinib; Quinazolines | 2012 |
15 other study(ies) available for lapatinib and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity.
Topics: Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A Inducers; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Incidence; Lapatinib; Multivariate Analysis; Neoplasm Metastasis; Retrospective Studies; Risk Factors | 2019 |
The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01.
Topics: Chemical and Drug Induced Liver Injury; HLA-DRB1 Chains; Humans; Lapatinib; Models, Molecular; Molecular Dynamics Simulation; Quinazolines; Tetanus Toxoid | 2015 |
[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemical and Drug Induced Liver Injury; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2016 |
No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; HLA-DRB1 Chains; Humans; Lapatinib; Lymphocyte Activation; Quinazolines; T-Lymphocytes | 2016 |
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.
Topics: Amoxicillin-Potassium Clavulanate Combination; Cell Adhesion Molecules; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; Genome-Wide Association Study; Genotype; HLA-B Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Lapatinib; Liver; Proteins; Quinazolines | 2017 |
Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Activation; Escherichia coli; Ferricyanides; Humans; Lapatinib; Mass Spectrometry; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Protein Binding; Quinazolines | 2011 |
Lapatinib-induced hepatitis: a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Jaundice; Lapatinib; Middle Aged; Quinazolines | 2011 |
Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.
Topics: Administration, Oral; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2012 |
Hepatotoxicity associated with lapatinib in an experimental rat model.
Topics: Alanine Transaminase; Albumins; Analysis of Variance; Animals; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Lapatinib; Lipoproteins, VLDL; Liver; Liver Function Tests; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triglycerides | 2012 |